MicroRNA-21 as therapeutic target in cancer and cardiovascular disease

Recent Patents on Cardiovascular Drug Discovery

Volumn 5, Issue 3, 2010, Pages 156-161

  Bonci, Désirée ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Cancer; Cardiovascular diseases; MicroRNAs; MiR 21; Patents

Indexed keywords

MICRORNA 21; MICRORNA ANTAGONIST; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER RESEARCH; CARDIOVASCULAR DISEASE; HUMAN; INTESTINE CANCER; LUNG CANCER; MOUSE; NEOPLASM; NONHUMAN; PANCREAS CANCER; PATENT; PRIORITY JOURNAL;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; MICE; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASMS; OLIGONUCLEOTIDES; UP-REGULATION;

EID: 78649992541     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489010793351962     Document Type: Article

References (53)

1. Baehrecke EH. miRNAs: Micro managers of programmed cell death. Curr Biol 2003; 13: R473-5.
2. Mendell JT. MicroRNAs: Critical regulators of development, cellular physiology and malignancy. Cell Cycle 2005; 4:1179-84.
3. Kuehbacher A, Urbich C, Dimmeler S. Targeting microRNA expression to regulate angiogenesis. Trends Pharmacol Sci 2008; 29:12-5.
4. de Moor CH, Meijer H, Lissenden S. Mechanisms of translational control by the 3' UTR in development and differentiation. Semin Cell Dev Biol 2005; 16: 49-58.
5. Jazbutyte V, Thum T. microRNA-21: From cancer to cardiovascular disease. Curr Drug Targets 2010; 11(8): 926-35.
6. Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K, et al. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 2010; 102: 883-91.
7. Gregersen LH, Jacobsen AB, Frankel LB, Wen J, Krogh A, Lund AH. MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One 2010; 5: e8836.
8. Sachdeva M, Mo YY. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 2010; 70: 378-87.
9. Elia L, Quintavalle M, Zhang J, Contu R, Cossu L, Latronico MV, et al. The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: Correlates with human disease. Cell Death Differ 2009; 16:1590-8.
10. Xin M, Small EM, Sutherland LB, Qi X, McAnally J, Plato CF, et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev 2009; 23: 2166-78.
11. Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 2007; 6: 60.
12. Cho WC. MicroRNAs in cancer - from research to therapy. Biochim Biophys Acta 2010; 1805: 209-17.
13. Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010; 102:1174-9.
14. Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 2004; 10:1957-66.
15. Krichevsky AM, Gabriely G. miR-21: A small multi-faceted RNA. J Cell Mol Med 2009; 13: 39-53.
16. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425-36.
17. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-61.
18. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005; 65: 6029-33.
19. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007; 67: 8699-707.
20. Lui WO, Pourmand N, Patterson BK, Fire A. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res 2007; 67: 6031-43.
21. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 2008; 14: 419-27.
22. Feber A, Xi L, Luketich JD, Pennathur A, Landreneau RJ, Wu M, et al. MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg 2008; 135: 255-60; discussion 260.
23. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008; 141: 672-5.
24. Connolly E, Melegari M, Landgraf P, Tchaikovskaya T, Tennant BC, Slagle BL, et al. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol 2008; 173: 856-64.
25. Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, et al. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol 2008; 28: 5369-80.
26. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133: 647-58.
27. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128-36.
28. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 2008; 283:1026-33.
29. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-Mediated tumor growth. Oncogene 2007; 26: 2799-803.
30. Croce, C.M., Calin, G.A. MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer. US20080261908 (2008).
31. Bader, A.G., Byrom, M., Johnson, C.D., Brown, D. MIR-21 regulated genes and pathways as targets for therapeutic intervention. WO2008073920 (2008).
32. Brown, D., Ford, L., Cheng, A., Jarvis, R., Byrom, M., Ovcharenko, D., Devroe, E., Kelnar, K. Methods and compositions involving miRNA and miRNA inhibitor molecules. US20090176723 (2009).
33. Huibregtse, S.B., Labourier, E., Elizondo, L. Micrornas differentially expressed in cervical cancer and uses thereof. US20090186348 (2009).
34. Obad, S., Kauppinen, S., Elmen, J., Lindow, M., Heidenblad, M. Micromirs. US20090143326 (2009).
35. Thum, T., Bauersachs, J. Microrna (mirna) for the diagnosis and treatment of heart diseases. US20100010073 (2010).
36. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007; 72: 397-402.
37. Croce, C.M., Calin, G.A., Volinia, S. Microrna-based methods and compositions for the diagnosis, prognosis and treatment of solid cancers. US20080306006 (2008).
38. Croce, C.M., Calin, G.A. Micro-RNA expression abnormalities of pancreatic, endocrine and acinar tumors. US20080306018 (2008).
39. Giovannetti E, Funel N, Peters GJ, Del Chiaro M, Erozenci LA, Vasile E, et al. MicroRNA-21 in pancreatic cancer: Correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 2010; 70: 4528-38.
40. Bader, A.G., Byrom, M., Johnson, C.D., Brown, D. mir-21 Regulated genes and pathways as targets for therapeutic intervention. US20090192102 (2009).
41. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65:7065-70.
42. Afonja O, Juste D, Das S, Matsuhashi S, Samuels HH. Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis. Oncogene 2004; 23: 8135-45.
43. Croce, C.M., Yanaihara, N., Harris, C.C. MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer. US20080306017 (2008).
44. Gao W, Yu Y, Cao H, Shen H, Li X, Pan S, et al. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother 2010; 64(6): 399-408.
45. van Rooij E, Marshall WS, Olson EN. Toward microRNA-based therapeutics for heart disease: The sense in antisense. Circ Res 2008; 103: 919-28.
46. Ji R, Cheng Y, Yue J, Yang J, Liu X, Chen H, et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res 2007; 100:1579-88.
47. Tatsuguchi M, Seok HY, Callis TE, Thomson JM, Chen JF, Newman M, et al. Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol 2007; 42:1137-41.
48. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456: 980-4.
49. Roy S, Khanna S, Hussain SR, Biswas S, Azad A, Rink C, et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 2009; 82: 21-9.
50. Sayed D, Rane S, Lypowy J, He M, Chen IY, Vashistha H, et al. MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol Biol Cell 2008; 19: 3272-82.
51. Olson, E., van Rooij, E. Compositions comprising a micro-RNA and methods of their use in regulating cardiac remodeling. WO2009058818 (2009).
52. Dong S, Cheng Y, Yang J, Li J, Liu X, Wang X, et al. MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem 2009; 284: 29514-25.
53. Cheng Y, Liu X, Zhang S, Lin Y, Yang J, Zhang C. MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4. J Mol Cell Cardiol 2009; 47: 5-14.